October 19th 2023
Expert perspectives from Shannon Westin, MD, MPH, FACOG, on frontline treatment options for patients with newly diagnosed low-grade serous ovarian cancer in the context of recent clinical trial data. Dr. Westin discusses optimizing treatment strategies while prioritizing quality of life and fertility preservation for patients.
September 10th 2020
Shannon N. Westin, MD, MPH, discusses remaining challenges in endometrial cancer.
May 12th 2020
Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.
May 11th 2020
January 18th 2019
Shannon N. Westin, MD, MPH, associate professor, The University of Texas MD Anderson Cancer Center, discusses advances made with PARP inhibitors in the ovarian cancer treatment paradigm.
November 20th 2018
Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses PARP inhibitors being tested in clinical trials.
October 9th 2018
Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.